38 İngilizce ve 87 Türkçe yayın, 5 kitap




Uluslar arası  İngilizce Yayınlar


1) Ertan A, Arimura A, Akdamar K, Shibata T, Groot K, Luciano M, Mather F,   Değertekin H, Agrawal N, Ryan J.: Pancreatic immunoreactive somatostatin and diabetes mellitus. Dig.Dis. and Sci. 1984;29:7,635
   
2) Değertekin H, Erten A, Akdamar Y, Yates R, Chen I, Coy DH, Arimura A.:Effects of somatostatin and a somatostatin agonist on diet-induced
   pancreatitis in mice. Peptide 1985; 6: 1245

3) Değertekin H, Ertan A, Yates R, Van Mater K, Akdamar K.: Hyperbaric oxygen,allopurional and diet-induced acute pancreatitis. Ann of Int.Med.; 1985;103: 3,  474

4) Değertekin H, Kestellioğlu F.: The prevalence of HBsAg in healthy people and  several liver diseases in Turkey. Asian Med.J.1986;  29:2,125  
 
5) Değertekin H, Akdamar K, YAtes R, Chen I, Ertan A, Vaupel R.: Light and  electron microscopic studies of diet-induced hepatic changes in mice. Acta Anat.1986; 125: 174

6) Ertan A, Değertekin H, Akdamar K, Godiwala T, Mather F.: A new criterion in the assesment of bentiromide as a test of exocrine pancreatic function in alcoholics. Pancreas 1986; 1: 176

7) Değertekin H, Ertan A, Akdamar K, Groot K, Godiwala T, Mather F, Arimura A.:Luminal gastric somatostatin-like immunoreactivity in response to various stimuli in man. Dig. Dis. and Sci.1986; 31: 833

8) Arimura A, Minamino N, Uehara A, Groot K, Değertekin H, Özden A, Akdamar K,Rossowski W, and Ertan A.: Somatostatin, CRF and GRF in the gastrointestinal tract. Proceedings 1987; 159:1666, Thailand.

9) Özden A, Değertekin H, Yeginsu O, Ertan A.: Mechanism of release of gastric  luminal somatostatin-like immunoreactivity in response to pentagastrin and sham feeding in man. Scand. J. of Gastroenterol.1987; 22: 1257-1262

10)Ertan A, Özden A, Golodner E, Değertekin H, Arimura A.: Gastric luminal  somatostatin secretion of normals and patients with pernicious anemia and with Zollinger-Ellison syndrome. Dig. Dis and Sci.1988; 33: 1596-1600

11)Yılmaz A, Tez M, Değertekin H.: Comparison of NMR water proton T 1   measurement in healthy and pathological blood. Spectroscopy. Letters 1989; 22(7),925-933

12) Göral V, Değertekin H, Aksoy N.: Colchicine in treatment of cirrhosis of  liver. Doğa, T.J. of Med. Sci.1992; 16 : 583-584

13) Göral V, Turhanoğlu M, Değertekin H, et al.: The prevalence of helicobacter  pylori in upper gastrointestinal diseases. JİMA 1992; 24: 53-57

14) Göral V, Değertekin H, Turfan M, et al.: The types of acute viral hepatitides in Turkey. JİMA 1993; 25: 60-62

15) Değertekin H, Göral V, Turhanoğlu M, Arıkan E.: The role of HCV in the etiology of liver cirrhosis in southeast Turkey. JİMA 1994; 26: 28-30

16) Göral V, Değertekin H, Canoruç F.: Asbestosis and gastrointestinal cancer in Southeast Turkey. Gastroenterology 1997; 112: 11.4, pp A.570

17) Değertekin H, Şit D. The prevalence of hepatocellular carcinoma in patients with liver cirrhosis in Southeastern Turkey. Turkish J Gastroenterol. 1998;9:217-220

18) Değertekin H, Yukselen AV, Dursun M, Yalcın K. Seroepidemiology of delta hepatitis in Turkey. Turkish J Gastroenterol 1999;10:319-323

19) Yalcın K, Değertekin H, Akkız H. HCV genotypes in HCV related chronic hepatitis in southeast Anatolia. Turkish J Gastroenterol. 1999;10:249-252

20) Değertekin H, Sari Y, Aslan S et al. Age  and sex distribution of colorectal carcinoma in the southeast of Turkey. Turkish J Gastroenterol.1999;10:153-156

21) Değertekin H, Tuzcu A, Yalçın A.  Horizontal transmission of HBV  infection among students in Turkey. Public Health, 2000; 114: 411-442

22) Değertekin H,Tuzcu A, Yalcın K. Horizontal transmission of HBV among students in the Southeastern Anatolia. Turkish J Gastroenterol. 2000;11:117-120

23) Değertekin  H, Sari Y,  Yalçın K,  Akgun Y. The age and sex distribution of colorectal carcinoma cases in Turkey. Hepato-Gastroenterol 2000; 47:32

24) Uzunalimoglu O, Yurdaydin C, Cetinkaya H, Bozkaya H, Sahin T, Colakoglu S, Tankurt E, Sarioglu M, Ozenirler S, Akkiz H, Tozun N, Degertekin H, Okten A.Risk factors for hepatocellular carcinoma in Turkey. Dig Dis Sci. 2001; 46(5):1022-1028

25) Değertekin. H, Yalçin K, Işık R. Peritoneal mesothelioma associated with exposure to asbestos in Southeastern Turkey. J Clin Gastroenterol, ; 35: 409,  2002

26) Yalçin, K,  Degertekin H. A 12-Month course of combination therapy with  interferon-alpha and ribavirin in chronic  hepatitis due to coinfection with  hepatitis B and C viruses. Clin Drug Invest, 2002; 22: 797-798

27) Yalçin, K, Degertekin H, Yildiz F,  Akkuş Z. A 12-Month course of  combination therapy with interferon-alfa and lamivudine in patients with chronic hepatitis Delta virus: A single-center, prospective, open label,uncontrolled study. Curr. Ther. Res, 2002;  63: 736-747

28) Yalçin, K, Degertekin H, Yildiz F, Celik Y.  Markers of disease activity in chronic hepatitis B virus infection. Clin Invest Med, 2003; 26: 27-34

29) Yalcin, K, Degertekin H, Yildiz F , Celik Y.  Twelve month courses of interferon alpha-2b and lamivudine in combination compared to interferon alpha-2b monotherapy in patients with untreated HBeAg-positive chronic hepatitis B.  Clin Infect Dis, 2003; 36: 1516-1522

30) Yalcin, K, Danis R, Degertekin H, Alp MN, Tekes S, Budak T. The lack of effect of therapeutic vaccination with a preS2/S HBV vaccine in the immune tolerant phase of chronic HBV infection. J Clin Gastroenterol, 2003; 37: 330-335

31) Yalcin, K, Acar M, Degertekin H. Specific vaccine therapy in inactive HBsAg carriers by recombinant hepatitis B vaccine: A randomised controlled trial.  Infection, 2003; 31: 221-225

32) Yalcin, K, Degertekin H, Yurdaydin C, Bozdayi M, Bozkaya H. The role of HBeAg seroconversion in acute exacerbation of liver disease with termination of hepatitis B and D virus infection in a chronic hepatitis D patient during alpha-interferon therapy.  Eur J Gastroenterol Hepatol, 2003;15: 820-823

33) Yalçın, K, Değertekin H, Yıldız F , Kılınç N.  A severe hepatitis flare in an HBV-HCV coinfected patient during combination therapy with α–interferon and ribavirin.  J Gastroenterol, 2003; 38: 796-800

34)  Yalcin, K, Degertekin H , Bozdayi M. A late failure of combined recombinant hepatitis B vaccine and lamivudine in treatment of a patient with chronic hepatitis B.  South Med J, 2004; 97: 407-409

35) Yalcin, K,Degertekin H, Bahcecioglu IH, Demir A, Aladag M, Yildirim B, Horasanli S, Ciftci S , Badur S. Hepatitis B virus genotype D prevails in patients with persistently elevated or normal ALT levels in Turkey. Infection, 2004; 32: 24-29  

36) Yalcin, K,Bilici A,  Ayyildiz O, Degertekin  H, Muftuoglu E, ‘Imaging of subcapsular liver hematoma and hepatic infarction in pregnancy complicated by the HELLP syndrome: a case report.  Eur J Radiol,2004;50: 21-26

37) Kılınç N, Yalcin K, Degertekin H, Özaydın M. Clear cell carsinoma of the liver: A case report, Turk J Gastroenterol, 2003; 14: 211-214

38) Yalcin K, Degertekin H,  Alp MN, Tekes S, Satıcı O, Budak T. Determination of serum hepatitis B virus DNA in chronic HbsAg carriers. Turk J Gastroenterol, 2003; 14: 157-163

39) Yalcin K, Degertekin H, Kökoglu ÖF,Ayaz C. A three-month course of lamivudine therapy in HbeAg-positive hepatitis B patients with normal aminotransferase levels. Turk J Gastroenterol, 2004; 15: 21-26

40) Soyoral Y, Süner A, Kıdır V, Arıtürk Z, Balakan O, Degertekin H. The effects of viral cirrhosis on cardiac ventricular function. Eur J Gen Med 2004; 1 (2):15-18

41) Değertekin H, Yalçın K, YakutM. The prevalence of hepatitis delta virus infection in acute and chronic liver diseases in Turkey: An analysis of clinical studies. Turk J Gastroenterol. 2006 Mar;17(1):25-34.